{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:40:52Z","timestamp":1787071252219,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Severe hypertension in pregnancy deserves prompt recognition and urgent effective reduction in order to reduce the risk of complications such as eclampsia and HELLP syndrome and to achieve desirable neonatal outcomes. There is a need for effective and safe parenteral antihypertensive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>We studied the effectiveness and safety of intravenous labetalol use in severe hypertension in pregnancy and post-partum period in a teaching hospital in Chhattisgarh in 101 women. IV labetalol was given as bolus doses till the blood pressures were controlled. Neonatal outcomes were recorded, and adverse effects such as hypotension, hypoglycemia, and neonatal asphyxia were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Intravenous labetalol given as a single bolus of 20 mg was efficacious in controlling blood pressures in 93 out of 101 (93%) women, and the rest were controlled with 1 or 2 additional doses in 1\u20133 hours. No neonatal deaths happened beyond the 13 intrauterine fetal deaths at presentation. No women developed any episodes of hypotension, tachycardia of more than 100, or nausea or vomiting on labetalol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Intravenous labetalol, even as a single bolus dose, is highly efficacious and is free of any major adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_185_24","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T14:19:28Z","timestamp":1725977968000},"page":"3788-3791","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of intravenous labetalol in severe pre-eclampsia and eclampsia at a teaching institution in Chhattisgarh"],"prefix":"10.4103","volume":"13","author":[{"given":"Rachna","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, CIMS, Bilaspur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta Raman","family":"Jogi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, CIMS, Bilaspur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"R1-20241104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4236\/ojog.2022.123022","article-title":"A cross-sectional study on current practice of the management of pregnancy induced hypertension and its maternal and foetal complications and outcome in the western part of the state of Libya","volume":"12","author":"Elghoudi","year":"2022","journal-title":"Open J Obstet Gynecol"},{"key":"R2-20241104","first-page":"e174","article-title":"ACOG Committee Opinion No. 767: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R3-20241104","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/1471-0528.16913","article-title":"Factors affecting use of magnesium sulphate for pre-eclampsia or eclampsia: A qualitative evidence synthesis","volume":"129","author":"Eddy","year":"2022","journal-title":"BJOG"},{"key":"R4-20241104","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R5-20241104","doi-asserted-by":"crossref","first-page":"441.e1","DOI":"10.1016\/j.ajog.2020.06.018","article-title":"Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: Effects on cerebral perfusion pressure","volume":"223","author":"Tolcher","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20241104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1471-0528.13463","article-title":"Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: A systematic review and meta-analysis","volume":"123","author":"Shekhar","year":"2016","journal-title":"BJOG"},{"key":"R7-20241104","doi-asserted-by":"crossref","first-page":"2235057","DOI":"10.1080\/14767058.2023.2235057","article-title":"Oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy: A systematic review and meta-analysis","volume":"36","author":"Li","year":"2023","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R8-20241104","article-title":"A study of IV labetalol versus oral nifedipine in severe hypertension in pregnancy (A prospective randomized comparative study)","volume":"21","author":"Kaur","year":"2021","journal-title":"GMCP J Res Med Edu"},{"key":"R9-20241104","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4314\/ahs.v23i1.34","article-title":"Comparison of efficacy of intravenous labetalol and intravenous hydralazine for management of pre-eclampsia in pregnant women","volume":"23","author":"Kausar","year":"2023","journal-title":"Afr Health Sci"},{"key":"R10-20241104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.21276\/obgyn.2021.8.1.22","article-title":"Comparative study of labetalol and nifedipine in management of hypertensive disorders of pregnancy in BRIMS tertiary care center","volume":"8","author":"Deshmukh","year":"2021","journal-title":"New Indian J OBGYN"},{"key":"R11-20241104","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/HJH.0000000000002256","article-title":"Neonatal effects of intrauterine metoprolol\/bisoprolol exposure during the second and third trimester: A cohort study with two comparison groups","volume":"38","author":"Kayser","year":"2020","journal-title":"J Hypertens"},{"key":"R12-20241104","first-page":"CD001449","article-title":"Drugs for treatment of very high blood pressure during pregnancy","author":"Duley","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20241104","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/AOG.0000000000003290","article-title":"Systolic hypertension, preeclampsia-related mortality, and stroke in California","volume":"133","author":"Judy","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R14-20241104","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: An open-label, randomised controlled trial","volume":"394","author":"Easterling","year":"2019","journal-title":"Lancet"},{"key":"R15-20241104","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/HYPERTENSIONAHA.119.13802","article-title":"In Utero antihypertensive medication exposure and neonatal outcomes: A data linkage cohort study","volume":"75","author":"Fitton","year":"2020","journal-title":"Hypertension"},{"key":"R16-20241104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-023-01234-8","article-title":"Beta-blockers in pregnancy: Clinical update","volume":"25","author":"Katsi","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"R17-20241104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12884-020-02909-9","article-title":"Preeclampsia management modalities and perinatal death: A retrospective study in Woldia general hospital","volume":"20","author":"Tlaye","year":"2020","journal-title":"BMC Pregnancy Childbirth"},{"key":"R18-20241104","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.3390\/ijerph19159616","article-title":"The risk for neonatal hypoglycemia and bradycardia after beta-blocker use during pregnancy or lactation: A systematic review and meta-analysis","volume":"19","author":"de Bruin","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R19-20241104","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"R20-20241104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/M18-0338","article-title":"\u03b2-blocker use in pregnancy and the risk for congenital malformations: An international cohort study","volume":"169","author":"Bateman","year":"2018","journal-title":"Ann Intern Med"},{"key":"R21-20241104","first-page":"e42332","article-title":"Comparing intravenous labetalol and intravenous hydralazine for managing severe gestational hypertension","volume":"15","author":"Ehikioya","year":"2023","journal-title":"Cureus"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_185_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:41Z","timestamp":1787067821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_185_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_185_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2024-02-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}